SCNN1A
SCNN1A is a gene that encodes the alpha subunit of the epithelial sodium channel (ENaC). ENaC is a part of the aldosterone-sensitive sodium reabsorption pathway in the kidney, lung, and sweat glands. Mutations in this gene can lead to various health conditions, including Liddle syndrome and pseudohypoaldosteronism type 1 (PHA1).
Function[edit]
The SCNN1A gene provides instructions for making a protein that is part of the ENaC. This channel, which is made up of three different subunits (alpha, beta, and gamma), transports sodium ions into cells. The alpha subunit, produced from the SCNN1A gene, plays a crucial role in maintaining the balance of sodium in the body. It helps control blood volume and blood pressure, and it also plays a role in the reabsorption of sodium in the kidney.
Clinical significance[edit]
Mutations in the SCNN1A gene can cause disorders related to an imbalance of sodium in the body. These include:
- Liddle syndrome: This is a form of inherited high blood pressure. Mutations in the SCNN1A gene that cause Liddle syndrome result in an overactive sodium channel, leading to increased reabsorption of sodium in the kidney. This can cause high blood pressure and low levels of potassium in the blood.
- Pseudohypoaldosteronism type 1 (PHA1): This is a disorder characterized by an inability to maintain the balance of sodium in the body. Mutations in the SCNN1A gene that cause PHA1 result in a sodium channel that is less active or inactive, leading to a decrease in the reabsorption of sodium in the kidney. This can cause low blood pressure and high levels of potassium in the blood.
See also[edit]
References[edit]
-
SCNN1A gene transcripts
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
Medical weight loss NYC | Affordable GLP-1 injections NYC | Budget GLP-1 weight loss shots Philadelphia | New Jersey medical weight loss | NYC medical weight loss | Philadelphia medical weight loss | Sleep clinic NYC | W8MD's Philadelphia GLP-1 doctor | Weight loss prescriptions NYC
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian